KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Net Income (2016 - 2025)

Historic Net Income for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to -$202.4 million.

  • Novavax's Net Income fell 6684.17% to -$202.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $341.7 million, marking a year-over-year increase of 21997.03%. This contributed to the annual value of -$187.5 million for FY2024, which is 6560.04% up from last year.
  • As of Q3 2025, Novavax's Net Income stood at -$202.4 million, which was down 6684.17% from $106.5 million recorded in Q2 2025.
  • Novavax's Net Income's 5-year high stood at $518.6 million during Q1 2025, with a 5-year trough of -$846.3 million in Q4 2021.
  • For the 5-year period, Novavax's Net Income averaged around -$142.7 million, with its median value being -$168.6 million (2022).
  • In the last 5 years, Novavax's Net Income plummeted by 191082.7% in 2021 and then soared by 45150.53% in 2025.
  • Over the past 5 years, Novavax's Net Income (Quarter) stood at -$846.3 million in 2021, then skyrocketed by 78.46% to -$182.2 million in 2022, then increased by 2.12% to -$178.4 million in 2023, then surged by 54.58% to -$81.0 million in 2024, then plummeted by 149.76% to -$202.4 million in 2025.
  • Its last three reported values are -$202.4 million in Q3 2025, $106.5 million for Q2 2025, and $518.6 million during Q1 2025.